EYA transcriptional coactivator and phosphatase 4Genealiases: CMD1J · DFNA10
Q-omics provides the consensus-scored EYA4 profile across patient tissues and cancer cell-line models. EYA4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, EYA4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, EYA4 RNA expression shows 16,824 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where EYA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EYA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EYA4 survival associations across molecular data types. EYA4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EYA4 RNA expression–survival associations across cancer types. High EYA4 expression shows unfavorable associations in KIRP, UCEC, UVM, STAD and ACC, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for EYA4 RNA expression.
This table summarizes EYA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for EYA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EYA4 shows lower tumor expression in KIRC, KICH, THCA, KIRP, BLCA and LUAD. The KIRC box plot shows higher EYA4 RNA expression in normal versus tumor tissue (log2 FC = −2.293, t-test p < 0.001).
This table shows molecular features associated with EYA4 in patient tissues and cancer cell lines. In patient samples, EYA4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, EYA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and CNS.
